Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?
- PMID: 18188549
- DOI: 10.1007/s00228-007-0440-z
Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?
Comment on
-
High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.Eur J Clin Pharmacol. 2008 Apr;64(4):357-65. doi: 10.1007/s00228-007-0412-3. Epub 2007 Dec 5. Eur J Clin Pharmacol. 2008. PMID: 18057928
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
